MAP.AX ASX
Microba Life Sciences Limited
1W: -3.9%
1M: -10.9%
3M: +28.9%
YTD: -46.7%
1Y: -42.4%
3Y: -85.2%
A$0.05 ($0.03)
-0.00 (-2.04%)
Weekly Expected Move ±6.8%
A$0
A$0
A$0
A$0
A$0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Cash Flow Trends
Operating Cash Flow
-$12M
-3.0% ▼
Capital Expenditures
$240K
+91.7% ▲
5Y CAGR: -18.6%
Free Cash Flow
-$13M
+15.4% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+100.0% ▲
Net Change in Cash
-$4M
+58.5% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$11M | -$13M | -$20M | $0 | -$21M |
| Depreciation & Amort. | $2M | $2M | $3M | $0 | $4M |
| Stock-Based Comp. | $642K | $421K | $0 | $0 | $0 |
| Change in Working Capital | -$253K | -$2M | $992K | $3M | $107K |
| Other Non-Cash Items | $3M | $6M | $509K | -$15M | $4M |
| Operating Cash Flow | -$10M | -$12M | -$16M | -$12M | -$12M |
| — Investing Activities — | |||||
| Capital Expenditures | -$2M | -$3M | -$1M | -$326K | -$4M |
| Acquisitions (Net) | $9K | $0 | -$10M | $0 | $103K |
| Investment Purchases | -$154K | $0 | $0 | $0 | $0 |
| Investment Sales | $228K | $0 | $0 | $66K | $0 |
| Other Investing | $58K | $38K | -$3M | -$3M | $0 |
| Investing Cash Flow | -$2M | -$3M | -$14M | -$3M | -$4M |
| — Financing Activities — | |||||
| Net Debt Issuance | $202K | -$5K | $60K | $820K | $1M |
| Stock Repurchased | -$2M | $0 | -$1M | -$385K | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | -$331K | -$548K | -$765K | -$897K | -$942K |
| Financing Cash Flow | $29M | $17M | $18M | $6M | $13M |
| Net Change in Cash | $18M | $1M | -$11M | -$9M | -$4M |
| Cash End of Period | $31M | $32M | $21M | $12M | $8M |
| Free Cash Flow | -$12M | -$15M | -$20M | -$15M | -$13M |